To date, primary and acquired resistance to EGFR TKIs, via EGFR-dependent as well as EGFR-independent mechanisms, remains a big challenge in the management of EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.